The fourth edition of Antibiotics Resistance Protocols, edited by Professor Stephen Gillespie, was published today. Part of Springer’s successful Methods in Molecular Biology book series, this edition showcases…
Visiting Scholar Isioma Doris Chukwu, a PhD student at the University of Jos in Nigeria, traveled to St Andrews for three weeks in late May. She worked with Infection and Global Health (IGH) Division members Principal…
A new study led by Principal Research Fellow Dr Wilber Sabiiti has found that antibiotics used to treat tuberculosis also kill other potentially useful bacteria. Such “good” bacteria play a key role in strengthening…
Medical research is one of the most important outputs for a university, with breakthroughs potentially saving lives around the world. Professor Stephen Gillespie and colleagues at the School of Medicine have done just…
The St Andrews tuberculosis research group together with global health partners have won a €4.9 million grant from the European Developing Countries Clinical Trials Partnership (EDCTP). Led by…
The Infection and Global Health Division recently welcome Dr Christine Sekaggya-Wiltshire and Dr Olive Mbabazi from Makarere University.
New medical advances could revolutionise the ability to treat undetected tuberculosis (TB) thanks to an international team of scientists led by the University of St Andrews.
Scientists at the School of Medicine are leading the medical monitoring of a new clinical trial to treat tuberculosis more quickly.
the first ever Molecular bacterial load assay (MBLA) stakeholders conference was held at the University of St Andrews, 11th – 13th June 2018.
Experts from around the world are gathered in St Andrews to learn how to dramatically cut the time needed to diagnose tuberculosis to save hundreds of thousands of lives.